DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Total Non-current Liabilities
All obligations due after more than one year.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 54.0% from a year ago
Total non-current liabilities stood at $97K at the end of Q1 FY2026, down 54.0% from a year earlier and down 24.2% from the prior quarter. Over 3 fiscal years it compounded at -31.6% a year.
Context
- Total non-current liabilities amounted to 0.2% of total assets at the end of Q1 FY2026, down 0.4 pp from a year earlier.
- Total non-current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -54.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 128K USD
- Year-over-year change
- -46.0%
- 4-year CAGR
- +155.6%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 128K | -46.0% |
| FY2024 | 2024-12-31 | 237K | -25.2% |
| FY2023 | 2023-12-31 | 317K | -20.8% |
| FY2022 | 2022-12-31 | 400K | +13233.3% |
| FY2021 | 2021-12-31 | 3K | — |
Total Non-current Liabilities vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 total non-current liabilities of $97K is the lowest of the 7 companies compared; the peer median is $30.26M.
- Its year-over-year change of -54.0% is the 5th highest of 6, against a peer median of +14.4%.
- Total non-current liabilities amounts to 0.2% of total assets for DMAC, versus a peer median of 7.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $232.69M | +383.5% | -15.3% | 20.1% | |
| Mar 2026 | $161.26M | -17.0% | -6.5% | 44.5% | |
| Mar 2026 | $56.77M | +156.3% | -10.9% | 13.5% | |
| Mar 2026 | $3.75M | +14.4% | +22.7% | 1.3% | |
BIOABioAge Labs, Inc. | Mar 2026 | $2.71M | -61.0% | -72.9% | 0.7% |
| Mar 2026 | $217K | — | — | 0.3% | |
| Mar 2026 | $97K | -54.0% | -31.6% | 0.2% | |
| Peer median (excluding DMAC) | $30.26M | +14.4% | -10.9% | 7.4% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.